Rural Communities at Risk: Global Liver Institute Champions Awareness for Rare Liver Diseases
01. Februar 2025 08:00 ET
|
Global Liver Institute
Washington, D.C., Feb. 01, 2025 (GLOBE NEWSWIRE) -- As rural healthcare access shrinks across the United States and remains limited worldwide, Global Liver Institute (GLI) is shining a spotlight on...
Rare Skin Disorders Market: Key Insights into Future Outlook and Trends of Pemphigus Vulgaris, Epidermolysis Bullosa, Palmoplantar Pustulosis, and Prurigo Nodularis | DelveInsight
17. Dezember 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Rare Skin Disorders Market: Key Insights into Future Outlook and Trends of Pemphigus Vulgaris, Epidermolysis Bullosa, Palmoplantar Pustulosis, and...
Latest Published 5 Rare Eye Diseases Market Reports by DelveInsight: Retinitis Pigmentosa, Stargardt Disease, Ocular Melanoma, Uveitis, and Neurotrophic Keratitis
16. Dezember 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Latest Published 5 Rare Eye Diseases Market Reports by DelveInsight: Retinitis Pigmentosa, Stargardt Disease, Ocular Melanoma, Uveitis, and...
Bionical Emas sells EMAS Pharma to Kester Capital following strategic review
09. Dezember 2024 02:00 ET
|
Bionical Emas
Bionical Emas, the Early Access Programs and Clinical Trial Supply business, is selling EMAS Pharma to Kester Capital and an incoming executive team.
Kester Capital backs experienced management team in acquiring EMAS Pharma
09. Dezember 2024 02:00 ET
|
EMAS Pharma
Kester Capital, alongside a new senior management team, has acquired EMAS Pharma, the clinical development division of Bionical Emas.
AlveoGene’s Novel, Inhaled Gene Therapy AVG-002 Receives Orphan Drug Designation from FDA for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency
03. Dezember 2024 04:00 ET
|
Alveogene
Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infants with few, if any, options for long-term survivalHighly encouraging preclinical data...
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
24. Oktober 2024 07:30 ET
|
Soligenix, Inc.
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
Nufactor® Receives URAC’s Full Certification as a Rare Disease Pharmacy Center of Excellence
17. September 2024 13:34 ET
|
FFF Enterprises.com
TEMECULA, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nufactor, Inc., a specialty infusion company and subsidiary of FFF Enterprises, Inc., is delighted to announce that it has received full...
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
07. August 2024 19:30 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a...
Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone
01. August 2024 09:00 ET
|
PRISM Mediawire
Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone